Advances in the treatment of ANCA-associated vasculitis

A review of how treatment of ANCA-associated vasculitis has shifted: rituximab is now established for both remission induction and maintenance, steroid doses have been cut substantially without losing efficacy, and the oral C5a receptor antagonist avacopan has been approved as an add-on. Newer agents including anti-CD19 CAR T cells and next-generation complement inhibitors are under investigation.